Clinical Trials for Chronic Kidney Disease
184 chronic kidney disease trials indexed, 74 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Chronic Kidney Disease
Chronic Kidney Disease (CKD) is a condition where the kidneys gradually lose their ability to function properly. The kidneys are vital organs responsible for filtering waste and excess fluids from the blood, which are then excreted in urine. In CKD, damage to the kidneys occurs over months or years, leading to a decline in filtration capacity. The underlying pathology often involves damage to the nephrons, the tiny filtering units inside the kidneys, due to factors like high blood pressure or diabetes. Diagnosis typically involves blood tests measuring creatinine levels to estimate the glomerular filtration rate (GFR), urine tests to check for protein, and imaging studies to assess kidney structure.
Common symptoms of CKD can be subtle in the early stages and may include fatigue, swelling in the legs or ankles, and changes in urination patterns. The condition is more common in adults over the age of 50, but it can affect people of all ages. Those most affected often have underlying health issues such as diabetes, hypertension, or a family history of kidney disease. Other risk factors include obesity, smoking, and certain ethnic backgrounds, such as African American or Hispanic populations, who tend to have higher rates of CKD.
CKD is a significant medical and social concern because it can progress to kidney failure, requiring dialysis or transplantation. According to recent data, about 15% of adults in the United States have some form of CKD. This prevalence means millions of people face increased risks of cardiovascular disease and premature death. Economically, CKD places a heavy burden on healthcare systems, with costs exceeding $120 billion annually in the U.S. alone. Early diagnosis and management are critical to slowing disease progression and improving quality of life.
The Chronic Kidney Disease Treatment Landscape
The first-line treatment for CKD focuses on controlling the underlying causes and slowing kidney damage. This usually involves managing blood pressure with medications such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Lifestyle changes are also recommended, including dietary adjustments to reduce salt intake, regular exercise, and quitting smoking. Monitoring kidney function regularly helps guide treatment adjustments. Early intervention aims to maintain kidney function and prevent complications like cardiovascular disease.
If first-line treatments are insufficient, second-line options include additional medications to control symptoms and complications. These can involve diuretics to reduce fluid buildup and phosphate binders to manage mineral imbalances. Some patients may also receive erythropoiesis-stimulating agents to treat anemia caused by reduced kidney function. In more advanced stages, third-line treatments may include preparations for dialysis or kidney transplantation. These options depend on the patient’s overall health and disease progression.
Despite available treatments, significant gaps remain. Some subgroups of patients, such as those with diabetic kidney disease, may respond poorly to existing therapies. Side effects from medications, including cough or elevated potassium levels, can limit their use. Additionally, many treatments do not fully prevent progression to end-stage renal disease. Current research is focused on developing new drugs that target specific pathways involved in kidney damage, reducing inflammation, and improving patient outcomes. Clinical trials continue to explore these areas to address unmet needs in CKD care.
Why Clinical Trials Matter for Chronic Kidney Disease
Clinical trials offer patients with CKD opportunities to access new treatments that are not yet widely available. Participating in a trial can provide closer health monitoring and contribute valuable information to medical research. Currently, there are 184 chronic kidney disease clinical trials indexed on ClinicalTrials.gov, with 74 actively recruiting participants. These trials investigate a range of interventions, from novel medications to lifestyle approaches, aiming to improve kidney function and patient quality of life.
Joining a clinical trial involves certain risks. The effectiveness of new treatments is not guaranteed, and some participants may receive a placebo instead of the active drug. Additional clinic visits and tests are often required, which can add to the burden of care. Side effects from experimental treatments may also occur, and their severity can vary. It is important for patients to discuss these factors with their healthcare providers to make informed decisions about trial participation.
The clinical trial landscape for CKD includes studies sponsored by academic institutions, pharmaceutical companies, and cooperative research groups. These sponsors work together to design and conduct trials that meet regulatory standards and ethical guidelines. ClinicalTrials.gov serves as a comprehensive registry and results database, helping patients and caregivers find relevant trials and understand their purposes. This transparency supports informed choices and advances in CKD treatment research.
What to Look for in a Chronic Kidney Disease Clinical Trial
Clinical trials are divided into four main phases. Phase 1 focuses on testing safety and dosage in a small group of participants. Phase 2 evaluates effectiveness and side effects in a larger group. Phase 3 compares the new treatment to standard care in even more participants. Phase 4 happens after approval to monitor long-term effects. For Chronic Kidney Disease trials, the current distribution shows 62 trials without a specified phase, 29 in Phase 3, 17 in Phase 2, and 11 in Phase 1. Phase 3 is the most common phase, reflecting ongoing efforts to confirm treatment benefits and risks.
Inclusion criteria are important to ensure the right participants join the study. For Chronic Kidney Disease, trials often specify age ranges, typically adults over 18 years. They may require certain stages of kidney disease, such as stage 3 or 4, identified by specific biomarkers like estimated glomerular filtration rate (eGFR). Prior treatments or medications may also be considered to ensure participants have a similar health background. Some studies include disease duration limits to focus on early or late-stage patients. These criteria help researchers study a consistent group and produce reliable results.
Exclusion criteria help protect participant safety and study integrity. Common exclusions in Chronic Kidney Disease trials include other serious health conditions like uncontrolled diabetes or heart failure. These comorbidities might affect how a treatment works or increase risks. Some trials exclude patients taking certain medications that could interact with the study drug. Safety thresholds, such as very low blood pressure or abnormal lab values, may also prevent enrollment. Understanding these exclusions can help patients and caregivers decide if a trial might be suitable.
Practical considerations matter when deciding to join a trial. The length of a study can range from a few months to several years. Visit schedules may require frequent trips to the clinic for tests and monitoring. Travel distance and costs should be discussed with the research team. Patients should ask four key questions: What are the possible benefits and risks? How often will I need to visit the study site? Are there costs or reimbursements for travel? What happens if I want to leave the trial early? Clear answers will help patients make informed choices about participation.
Primary Sources and Further Reading
For those interested in learning more about Chronic Kidney Disease and clinical trials, several reliable sources provide detailed and up-to-date information. These websites offer guidance on kidney health, research opportunities, and patient resources. Exploring these materials can help patients and caregivers understand their options and prepare for discussions with healthcare providers.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Kidney Disease
- MedlinePlus - Kidney Diseases
- ClinicalTrials.gov - Chronic Kidney Disease Studies
- Centers for Disease Control and Prevention - Chronic Kidney Disease
Latest Research and Emerging Treatments for Chronic Kidney Disease (2026)
Chronic kidney disease treatment is evolving with several Phase 3 trials exploring new options to reduce risks for patients. One study is testing low dose rivaroxaban, an oral blood thinner, in people with advanced chronic kidney disease and high cardiovascular risk (NCT03969953). Rivaroxaban works by helping prevent blood clots, which may lower the chance of heart attacks and strokes. For patients, this could mean fewer serious heart-related events while managing kidney disease.
Another promising area involves drugs like ziltivekimab, an injectable medicine studied in patients with chronic kidney disease, cardiovascular disease, and inflammation (NCT05021835). Ziltivekimab targets inflammation, which is thought to contribute to worsening kidney and heart problems. If effective, this treatment might offer a new way to reduce complications linked to inflammation for people living with these conditions.
New drugs for chronic kidney disease also include oral therapies like orforglipron and combination treatments such as baxdrostat with dapagliflozin. Orforglipron is being compared to insulin glargine in adults with type 2 diabetes and obesity at increased cardiovascular risk (NCT05803421). It belongs to a class that may help control blood sugar with a pill instead of injections. The combination of baxdrostat and dapagliflozin is under study for its potential to protect kidney function and lower heart risks in patients with chronic kidney disease and high blood pressure (NCT06742723). These options, if successful, could provide more convenient or effective choices for managing chronic kidney disease and related health issues.
Frequently asked questions about Chronic Kidney Disease trials
How do I find Chronic Kidney Disease clinical trials?
The authoritative source for Chronic Kidney Disease clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 184 chronic kidney disease studies are currently indexed. You can search by entering "chronic kidney disease" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new chronic kidney disease trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Chronic Kidney Disease trials in?
Across the 184 chronic kidney disease trials TrialsAlert indexes, the most common phase is Phase 3. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Chronic Kidney Disease clinical trials are currently recruiting?
As of the latest scan, 74 chronic kidney disease trials have a "Recruiting" status on ClinicalTrials.gov, out of 184 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting chronic kidney disease trial matches their tracked condition.
Stay informed about chronic kidney disease research
Get a weekly briefing with the trials that matter most.